The Collaborative Group, Ltd., and Abbott Laboratories have signed a worldwide, exclusive license agreement granting Abbott access to Collaborative’s technology relating to fungal beta (1,3)-glucan detection reagents for human fungal diagnostic assay development and commercialization.
The technology allows easy integration with a variety of diagnostic assay formats, and also provides improved performance over other existing fungal detection methods.
This worldwide, exclusive license allows Abbott to develop, manufacture, and sell in vitro diagnostic products for detecting or monitoring fungal infection in samples derived from humans.
Collaborative will receive an up-front license fee upon signing and milestone payments upon first commercial sale of a licensed product, in addition to royalties on net sales. “This agreement signifies another important development in Collaborative’s intellectual property strategy,” stated Charles Ryan, Vice President, Technology Management and General Counsel of The Collaborative Group.
“This agreement provides Abbott with an innovative technology to develop human fungal diagnostic products which we believe has significant potential for addressing an important medical problem,” Ryan added. Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products.
The company employs 57,000 people and markets its products in more than 130 countries.
The Collaborative Group, Ltd., founded in 1990, is a privately held, full- service bioscience technology company focused on the provision of seamless research, development and manufacturing services to the biopharmaceutic, cosmetic, and personal care industries worldwide.
Collaborative also adds value to its client’s technology by offering platform technologies related to controlled delivery systems and formulation.